Breast Cancer
Conditions
Interventions
Docetaxel 75mg/m2 day1, Cyclophosphamide 100mg/m2 day1-14 every 3 weeks, 4 cycles
Sponsors
Shiga University of Medical Science
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically deterimined breast cancer 2. Age 20 to 65 years 3. ECOG performance status 0 or 1 4. The patient of possible beginning of the treatment within four weeks after it operates 5. Previous endocrine therapy or chemotherapy for breast cancer 6. Required baseline laboratory parameters WBC >= 3,500/mm3 Neu >= 1,500/mm3 Hb >= 10.0g/dL Plt >= 100,000/mm3 T-Bil <= 1.5mg/dL AST <= 60 IU/L ALT <= 60 IU/L Cre <= 1.5mg/dL normal ECG 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Bilateral breast cancer in same time 2. Active double cancer 3. Inflammatory breast cancer 4. Male breast cancer 5. Severe drug allergic history 6. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infartion within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency) 7. Active infections 8. Peripheral nerve disorders 9. Massive pleural or pericardial effusion 10. Severe edema 11. Interstitial lung disease, pulmonary fibrosis 12. The case which has an underlying disease which needs combined use with steroid 13. Psychiatric disease 14. Pregnant or lactating women 15. Other conditions not suitable for this study 16. Allergy against polysorbert 80
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Disease-free survival | — |
Countries
Japan
Outcome results
None listed